Cytochrome P450 and non-cytochrome P450 oxidative metabolism: Contributions to the pharmacokinetics, safety, and efficacy of xenobiotics

Drug Metabolism and Disposition

Volumn 44, Issue 8, 2016, Pages 1229-1245

  Foti, Robert S ^a   Dalvie, Deepak K ^b  

^a AMGEN INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' IMINODIPROPIONITRILE; ALBENDAZOLE; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ALDEHYDE OXIDASE; ALDO KETO REDUCTASE; ALIPHATIC COMPOUND; AMINE OXIDASE (FLAVIN CONTAINING); AROMATIC HYDROXYL GROUP; CARBONYL REDUCTASE; CARBOXYLESTERASE; CLOPIDOGREL; CYTOCHROME P450; DELEOBUVIR; DIMETHYLANILINE MONOOXYGENASE; EPOXIDE HYDROLASE; ETHIONAMIDE; FAMCICLOVIR; FENBENDAZOLE; GEMFIBROZIL; GLUCURONOSYLTRANSFERASE; HYDROXYL GROUP; KETOCONAZOLE; OXIDOREDUCTASE; RIPASUDIL; SULFOTRANSFERASE; THIOACETAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE OXIDASE; XENOBIOTIC AGENT;

AEROBIC METABOLISM; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENDOPLASMIC RETICULUM; ENZYME ANALYSIS; ENZYME SUBSTRATE COMPLEX; GLUCOSE METABOLISM; HUMAN; HYDROPHILICITY; LIPID METABOLISM; NONHUMAN; NUCLEOPHILICITY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; SULFATION; ANIMAL; DRUG INACTIVATION; ENZYME SPECIFICITY; METABOLIC ACTIVATION; METABOLISM; OXIDATION REDUCTION REACTION;

ACTIVATION, METABOLIC; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONOSYLTRANSFERASE; HUMANS; INACTIVATION, METABOLIC; OXIDATION-REDUCTION; OXIDOREDUCTASES; SUBSTRATE SPECIFICITY; SULFOTRANSFERASES; XENOBIOTICS;

EID: 84978115899     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.116.071753     Document Type: Review

References (218)

1. Achour B, Russell MR, Barber J, and Rostami-Hodjegan A (2014) Simultaneous quantification of the abundance of several cytochrome P450 and uridine 59-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos 42:500-510.
2. Ahmed F, Vyas V, Cornfield A, Goodin S, Ravikumar TS, Rubin EH, and Gupta E (1999) In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Res 19 (3A): 2067-2071.
3. Akabane T, Tanaka K, Irie M, Terashita S, and Teramura T (2011) Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41:372-384.
4. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
5. Barr JT, Jones JP, Joswig-Jones CA, and Rock DA (2013) Absolute quantification of aldehyde oxidase protein in human liver using liquid chromatography-tandem mass spectrometry. Mol Pharm 10:3842-3849.
6. Barr JT, Jones JP, Oberlies NH, and Paine MF (2015) Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance. Drug Metab Dispos 43:34-41.
7. Barski OA, Tipparaju SM, and Bhatnagar A (2008) The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 40:553-624.
8. Beaumont K, Webster R, Gardner I, and Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 4:461-485.
9. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, Allayee H, Lee R, Graham M, and Crooke R, et al. (2013) Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 17:49-60.
10. Bernlochner I and Sibbing D (2012) Thienopyridines and other ADP-receptor antagonists. Handbook Exp Pharmacol 210:165-198.
11. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, and Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36: 386-399.
12. Bohnert T, Patel A, Templeton I, Chen Y, Lu C, Lai G, Leung L, Tse S, Einolf HJ, and Wang YH, et al. (2016) Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions-an industry perspective. Drug Metab Dispos DOI: 10.1124/[published ahead of print].
13. Bourland JA, Martin DK, and Mayersohn M (1997) Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: preliminary in vitro findings using a rat liver preparation. J Pharm Sci 86:1494-1496.
14. Boyer CS and Petersen DR (1992) Enzymatic basis for the transesterification of cocaine in the presence of ethanol: evidence for the participation of microsomal carboxylesterases. J Pharmacol Exp Ther 260:939-946.
15. Burchell B (1999) Transformation reactions: glucuronidation, in Handbook of Drug Metabolism (Woolf TF ed) pp 153-173, Marcel Dekker, Inc., New York.
16. Burchell B, Brierley CH, Monaghan G, and Clarke DJ (1998) The structure and function of the UDP-glucuronosyltransferase gene family. Adv Pharmacol 42:335-338.
17. Cashman JR (2008) Role of flavin-containing monooxygenase in drug development. Expert Opin Drug Metab Toxicol 4:1507-1521.
18. Castagnoli N, Jr, Chiba K, and Trevor AJ (1985) Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 36:225-230.
19. Cerny MA (2016) Prevalence of non-cytochrome P450-mediated metabolism in FDA approved oral and intravenous drugs: 2006-2015. Drug Metab Dispos 44:1246-1252.
20. Cesura AM, Imhof R, Galva MD, Kettler R, and Da Prada M (1988) Interactions of the novel inhibitors of MAO-B Ro 19-6327 and Ro 16-6491 with the active site of the enzyme. Pharmacol Res Commun 20 (Suppl 4):51-61.
21. Chen Y, Zane NR, Thakker DR, and Wang MZ (2016) Quantification of flavin-containing monooxygenases 1, 3 and 5 in human liver microsomes by UPLC-MRM-based targeted quantitative proteomics and its application to the study of ontogeny. Drug Metab Dispos 44:975-983.
22. Chen Z, Zhang J, and Stamler JS (2002) Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 99:8306-8311.
23. Chiba K, Peterson LA, Castagnoli KP, Trevor AJ, and Castagnoli N, Jr (1985a) Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Drug Metab Dispos 13:342-347.
24. Chiba K, Trevor AJ, and Castagnoli N, Jr (1985b) Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128:1228-1232.
25. Chou HC, Lang NP, and Kadlubar FF (1995a) Metabolic activation of N-hydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase(s). Cancer Res 55:525-529.
26. Chou HC, Lang NP, and Kadlubar FF (1995b) Metabolic activation of the N-hydroxy derivative of the carcinogen 4-aminobiphenyl by human tissue sulfotransferases. Carcinogenesis 16: 413-417.
27. Chou HC, Ozawa S, Fu PP, Lang NP, and Kadlubar FF (1998) Metabolic activation of methylhydroxylated derivatives of 7,12-dimethylbenz[a]anthracene by human liver dehydroepiandrosteronesteroid sulfotransferase. Carcinogenesis 19:1071-1076.
28. Choughule KV, Joswig-Jones CA, and Jones JP (2015) Interspecies differences in the metabolism of methotrexate: an insight into the active site differences between human and rabbit aldehyde oxidase. Biochem Pharmacol 96:288-295.
29. Clarke SE, Harrell AW, and Chenery RJ (1995) Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 23:251-254.
30. Coelho C, Foti A, Hartmann T, Santos-Silva T, Leimkühler S, and Romão MJ (2015) Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase. Nat Chem Biol 11: 779-783.
31. Coelho C, Mahro M, Trincão J, Carvalho AT, Ramos MJ, Terao M, Garattini E, Leimkühler S, and Romão MJ (2012) The first mammalian aldehyde oxidase crystal structure: insights into substrate specificity. J Biol Chem 287:40690-40702.
32. Coller JK, Fritz P, Zanger UM, Siegle I, Eichelbaum M, Kroemer HK, and Mürdter TE (2001) Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours. Histochem J 33:329-336.
33. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nüssler A, Neuhaus P, Zanger UM, and Eichelbaum M, et al. (2002) The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157-167.
34. Coughtrie MW and Fisher MB (2003) The role of sulfotransferases (SULTs) and UDPGlucuronosyltransferases (UGTs) in human drug clearance and bioactivation, in Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development (Lee JS, Obach RS, and Fisher MB eds) pp 551-567, Marcel Dekker/FontisMedia, New York.
35. Crofton KM, Zhao X, Sayre LM, and Genter MB (1996) Characterization of the effects of N-hydroxy-IDPN on the auditory, vestibular, and olfactory systems in rats. Neurotoxicol Teratol 18:297-303.
36. Daci A, Beretta G, Vllasaliu D, Shala A, Govori V, Norata GD, and Krasniqi S (2015) Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients. PLoS One 10: e0142408.
37. Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, Obach RS, and O'Donnell JP (2002) Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem Res Toxicol 15: 269-299.
38. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, and Williams KM (2007) Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 46:623-644.
39. Decker M, Arand M, and Cronin A (2009) Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch Toxicol 83:297-318.
40. Diamond S, Boer J, Maduskuie TP, Jr, Falahatpisheh N, Li Y, and Yeleswaram S (2010) Speciesspecific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277-1285.
41. Diao X, Pang X, Xie C, Guo Z, Zhong D, and Chen X (2014) Bioactivation of 3-n-butylphthalide via sulfation of its major metabolite 3-hydroxy-NBP: mediated mainly by sulfotransferase 1A1. Drug Metab Dispos 42:774-781.
42. Dieckhaus CM, Miller TA, Sofia RD, and Macdonald TL (2000) A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Drug Metab Dispos 28:814-822.
43. Dieckhaus CM, Thompson CD, Roller SG, and Macdonald TL (2002) Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact 142:99-117.
44. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173.
45. Dittrich Ch, Greim G, Borner M, Weigang-Köhler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, and Fumoleau P (2002) Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38:1072-1080.
46. Dixon CM, Park GR, and Tarbit MH (1994) Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 47:1253-1257.
47. Dourado DF, Fernandes PA, and Ramos MJ (2008) Mammalian cytosolic glutathione transferases. Curr Protein Pept Sci 9:325-337.
48. Dutton GJ (1997) Raising the colors: personal reflections on the glucuronidation revolution 1950-1970. Drug Metab Rev 29:997-1024.
49. Eksterowicz J, Rock DA, Rock BM, Wienkers LC, and Foti RS (2014) Characterization of the active site properties of CYP4F12. Drug Metab Dispos 42:1698-1707.
50. El-Sherbeni AA and El-Kadi AO (2014) The role of epoxide hydrolases in health and disease. Arch Toxicol 88:2013-2032.
51. Ettmayer P, Amidon GL, Clement B, and Testa B (2004) Lessons learned from marketed and investigational prodrugs. J Med Chem 47:2393-2404.
52. Farid NA, Kurihara A, and Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50: 126-142.
53. Fasinu P, Bouic PJ, and Rosenkranz B (2012) Liver-based in vitro technologies for drug biotransformation studies - a review. Curr Drug Metab 13:215-224.
54. Foti RS and Fisher MB (2012) UDP-glucuronosyltransferases: pharmacogenetics, functional characterization and clinical relevance, in Encyclopedia of Drug Metabolism and Interactions (Lyubimov A ed) vol 1, part II, pp 1-71, Wiley, Hoboken, NJ.
55. Foti RS, Rock DA, Wienkers LC, and Wahlstrom JL (2012) Mechanisms of drug metabolism, in Encyclopedia of Drug Metabolism and Interactions (Lyubimov A ed) vol 1, part III, pp 1-68, Wiley, Hoboken, NJ.
56. Foti RS, Tyndale RF, Garcia KL, Sweet DH, Nagar S, Sharan S, and Rock DA (2015) "Target-site" drug metabolism and transport. Drug Metab Dispos 43:1156-1168.
57. Fu C, Di L, Han X, Soderstrom C, Snyder M, Troutman MD, Obach RS, and Zhang H (2013) Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationship. Drug Metab Dispos 41:1797-1804.
58. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, and McManus ME (2006) Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5-22.
59. Garattini E and Terao M (2012) The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487-503.
60. Gerlach M, Riederer P, Przuntek H, and Youdim MB (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 208:273-286.
61. Ghersi-Egea JF, Leninger-Muller B, Suleman G, Siest G, and Minn A (1994) Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J Neurochem 62:1089-1096.
62. Ghersi-Egea JF, Perrin R, Leininger-Muller B, Grassiot MC, Jeandel C, Floquet J, Cuny G, Siest G, and Minn A (1993) Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. Biochem Pharmacol 45: 647-658.
63. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
64. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, and Boschat J (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256-260.
65. Giorgi MA, Cohen Arazi H, Gonzalez CD, and Di Girolamo G (2011) Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother 12:1285-1295.
66. Greenawalt JW and Schnaitman C (1970) An appraisal of the use of monoamine oxidase as an enzyme marker for the outer membrane of rat liver mitochondria. J Cell Biol 46: 173-179.
67. Grilo NM, Antunes AM, Caixas U, Marinho AT, Charneira C, Conceição Oliveira M, Monteiro EC, Matilde Marques M, and Pereira SA (2013) Monitoring abacavir bioactivation in humans: screening for an aldehyde metabolite. Toxicol Lett 219:59-64.
68. Grilo NM, Charneira C, Pereira SA, Monteiro EC, Marques MM, and Antunes AM (2014) Bioactivation to an aldehyde metabolite-possible role in the onset of toxicity induced by the anti-HIV drug abacavir. Toxicol Lett 224:416-423.
69. Guengerich FP (2005) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry(Ortiz de Montellano PR ed) pp 377-530, Kluwer Academic/Plenum, New York.
70. Halpert JR, Domanski TL, Adali O, Biagini CP, Cosme J, Dierks EA, Johnson EF, Jones JP, Ortiz de Montellano P, and Philpot RM, et al. (1998) Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism. Drug Metab Dispos 26: 1223-1231.
71. Harris TR and Hammock BD (2013) Soluble epoxide hydrolase: gene structure, expression and deletion. Gene 526:61-74.
72. Hennessy DR, Steel JW, Lacey E, Eagleson GK, and Prichard RK (1989) The disposition of albendazole in sheep. J Vet Pharmacol Ther 12:421-429.
73. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, and Steel H (2001) Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23:1603-1614.
74. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, and Zanger UM (2008) Aberrant splicing caused by single nucleotide polymorphism c.516G.T [Q172H], a marker of CYP2B6∗6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325:284-292.
75. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, and Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247.
76. Humerickhouse R, Lohrbach K, Li L, Bosron WF, and Dolan ME (2000) Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60: 1189-1192.
77. Hutzler JM, Cerny MA, Yang YS, Asher C, Wong D, Frederick K, and Gilpin K (2014) Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382. Drug Metab Dispos 42:1751-1760.
78. Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J, and Fisher MB (2012) Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos 40:267-275.
79. Infante JR, Rugg T, Gordon M, Rooney I, Rosen L, Zeh K, Liu R, Burris HA, and Ramanathan RK (2013) Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET. Invest New Drugs 31:363-369.
80. Inoue K, Mizuo H, Kawaguchi S, Fukuda K, Kusano K, and Yoshimura T (2014) Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase. Drug Metab Dispos 42: 1326-1333.
81. Isobe T, Ohta M, Kaneko Y, and Kawai H (2016) Species differences in metabolism of ripasudil (K-115) are attributed to aldehyde oxidase. Xenobiotica 46:579-590.
82. Iyanagi T and Mason HS (1973) Some properties of hepatic reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase. Biochemistry 12:2297-2308.
83. Jacobson AR, Coffin SH, Shearson CM, and Sayre LM (1987) beta,beta'-Iminodipropionitrile (IDPN) neurotoxicity: a mechanistic hypothesis for toxic activation. Mol Toxicol 1:17-34.
84. Jhee SS, Shiovitz T, Crawford AW, and Cutler NR (2001) Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 40: 189-205.
85. Ji T, Ikehata K, Koen YM, Esch SW, Williams TD, and Hanzlik RP (2007) Covalent modification of microsomal lipids by thiobenzamide metabolites in vivo. Chem Res Toxicol 20:701-708.
86. Jin F, Robeson M, Zhou H, Moyer C, Wilbert S, Murray B, and Ramanathan S (2015) Clinical drug interaction profile of idelalisib in healthy subjects. J Clin Pharmacol 55:909-919.
87. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285-1297.
88. Johnston JP, Kane PO, and Kibby MR (1967) The metabolism of ethionamide and its sulphoxide. J Pharm Pharmacol 19:1-9.
89. Kanazawa I (1994) Short review on monoamine oxidase and its inhibitors. Eur Neurol 34 (Suppl 3):36-39.
90. Kapetanovic IM, Torchin CD, Strong JM, Yonekawa WD, Lu C, Li AP, Dieckhaus CM, Santos WL, Macdonald TL, and Sofia RD, et al. (2002) Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem Biol Interact 142:119-134.
91. Kaphalia BS, Mericle KA, and Ansari GA (2004) Mechanism of differential inhibition of hepatic and pancreatic fatty acid ethyl ester synthase by inhibitors of serine-esterases: in vitro and cell culture studies. Toxicol Appl Pharmacol 200:7-15.
92. Kawakami H, Ohtsuki S, Kamiie J, Suzuki T, Abe T, and Terasaki T (2011) Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci 100: 341-352.
93. Kaye B, Offerman JL, Reid JL, Elliott HL, and Hillis WS (1984) A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 14:935-945.
94. Kaye B, Rance DJ, and Waring L (1985) Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man. Xenobiotica 15:237-242.
95. Keogh JP (2012) Membrane transporters in drug development. Adv Pharmacol 63:1-42.
96. Khanna R, Morton CL, Danks MK, and Potter PM (2000) Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 60:4725-4728.
97. Kirischian NL and Wilson JY (2012) Phylogenetic and functional analyses of the cytochrome P450 family 4. Mol Phylogenet Evol 62:458-471.
98. Klaassen CD and Boles JW (1997) Sulfation and sulfotransferases 5: the importance of 39-phosphoadenosine 59-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J 11:404-418.
99. Klein K, Winter S, Turpeinen M, Schwab M, and Zanger UM (2010) Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol 1:129.
100. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, and Hines RN (2004) Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308:965-974.
101. Krenitsky TA, Hall WW, de Miranda P, Beauchamp LM, Schaeffer HJ, and Whiteman PD (1984) 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. Proc Natl Acad Sci USA 81:3209-3213.
102. Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, Karplus PA, Furnes B, Schlenk D, and Williams DE (2009) Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K. Drug Metab Dispos 37:1785-1791.
103. Laizure SC, Parker RB, Herring VL, and Hu ZY (2014) Identification of carboxylesterasedependent dabigatran etexilate hydrolysis. Drug Metab Dispos 42:201-206.
104. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, and Wrighton SA, et al. (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906-922.
105. Lamego J, Ferreira P, Alves M, Matias A, and Simplício AL (2015) Comparison of in vitro methods for carboxylesterase activity determination in immortalized cells representative of the intestine, liver and kidney. Mol Cell Probes 29:215-222.
106. Langenfeld E, Zanger UM, Jung K, Meyer HE, and Marcus K (2009) Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics 9: 2313-2323.
107. Lasker JM, Wester MR, Aramsombatdee E, and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28.
108. Lee JS, Obach RS, and Fisher MB (2003) Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development, FontisMedia/Marcel Dekker Inc., New York.
109. Lillibridge JA, Kalhorn TF, and Slattery JT (1996) Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab Dispos 24:1174-1179.
110. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
111. Liu L, Halladay JS, Shin Y, Wong S, Coraggio M, La H, Baumgardner M, Le H, Gopaul S, and Boggs J, et al. (2011) Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab Dispos 39:1840-1849.
112. Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJ, van Doorn L, Hellemans P, de Bono JS, and Eskens FA (2015) The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species-specific insoluble metabolite formation. Clin Cancer Res 21:2297-2304.
113. Lotti M, Ketterman A, Waskell L, and Talcott RE (1983) Meperidine carboxylesterase in mouse and human livers. Biochem Pharmacol 32:3735-3738.
114. Malátková P and Wsól V (2014) Carbonyl reduction pathways in drug metabolism. Drug Metab Rev 46:96-123.
115. Marchitti SA, Brocker C, Stagos D, and Vasiliou V (2008) Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 4:697-720.
116. Maret G, Testa B, Jenner P, el Tayar N, and Carrupt PA (1990) The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism. Drug Metab Rev 22:291-332.
117. Marriner SE and Bogan JA (1981) Pharmacokinetics of fenbendazole in sheep. Am J Vet Res 42: 1146-1148.
118. Matsui M and Homma H (1994) Biochemistry and molecular biology of drug-metabolizing sulfotransferase. Int J Biochem 26:1237-1247.
119. McKay JA, Weaver RJ, Murray GI, Ewen SW, Melvin WT, and Burke MD (1995) Localization of microsomal epoxide hydrolase in normal and neoplastic human kidney. J Histochem Cytochem 43:615-620.
120. McMahon RE, Marshall FJ, and Culp HW (1965) The nature of the metabolites of acetohexamide in the rat and in the human. J Pharmacol Exp Ther 149:272-279.
121. Michaels S and Wang MZ (2014) The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug Metab Dispos 42:1241-1251.
122. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
123. Morandi A, Gambetti P, Arora PK, and Sayre LM (1987) Mechanism of neurotoxic action of beta, beta'-iminodipropionitrile (IDPN): N-hydroxylation enhances neurotoxic potency. Brain Res 437:69-76.
124. Munger JS, Shi GP, Mark EA, Chin DT, Gerard C, and Chapman HA (1991) A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. J Biol Chem 266:18832-18838.
125. Nace CG, Genter MB, Sayre LM, and Crofton KM (1997) Effect of methimazole, an FMO substrate and competitive inhibitor, on the neurotoxicity of 3,39-iminodipropionitrile in male rats. Fundam Appl Toxicol 37:131-140.
126. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, and Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36: 1461-1464.
127. Naraharisetti SB, Lin YS, Rieder MJ, Marciante KD, Psaty BM, Thummel KE, and Totah RA (2010) Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos 38:889-893.
128. Nelson SD and Trager WF (2003) The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Dispos 31:1481-1498.
129. Nishi K, Huang H, Kamita SG, Kim IH, Morisseau C, and Hammock BD (2006) Characterization of pyrethroid hydrolysis by the human liver carboxylesterases hCE-1 and hCE-2. Arch Biochem Biophys 445:115-123.
130. Noguchi M, Kimoto A, Gierse JK, Walker MC, Zweifel BS, Nozaki K, and Sasamata M (2005) Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites. Biol Pharm Bull 28:2075-2079.
131. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
132. Obach RS, Huynh P, Allen MC, and Beedham C (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19.
133. Ohara H, Miyabe Y, Deyashiki Y, Matsuura K, and Hara A (1995) Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 50:221-227.
134. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, and Ebner T, et al. (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:83-92.
135. Oppermann U (2007) Carbonyl reductases: the complex relationships of mammalian carbonyl-and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47: 293-322.
136. Ortiz de Montellano PR and De Voss JJ (2002) Oxidizing species in the mechanism of cytochrome P450. Nat Prod Rep 19:477-493.
137. Overby LH, Carver GC, and Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29-45.
138. Pacifici GM, Temellini A, Giuliani L, Rane A, Thomas H, and Oesch F (1988) Cytosolic epoxide hydrolase in humans: development and tissue distribution. Arch Toxicol 62:254-257.
139. Pellock JM (1999) Felbamate. Epilepsia 40 (Suppl 5):S57-S62.
140. Pellock JM, Faught E, Leppik IE, Shinnar S, and Zupanc ML (2006) Felbamate: consensus of current clinical experience. Epilepsy Res 71:89-101.
141. Pue MA, Pratt SK, Fairless AJ, Fowles S, Laroche J, Georgiou P, and Prince W (1994) Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother 33:119-127.
142. Qian L and Ortiz de Montellano PR (2006) Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. Chem Res Toxicol 19:443-449.
143. Radominska-Pandya A, Ouzzine M, Fournel-Gigleux S, and Magdalou J (2005) Structure of UDP-glucuronosyltransferases in membranes. Methods Enzymol 400:116-147.
144. Rashidi MR, Smith JA, Clarke SE, and Beedham C (1997) In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 25:805-813.
145. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, and Savolainen J (2008) Prodrugs: design and clinical applications. Nat Rev Drug Discov 7:255-270.
146. Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, and McConn DJ (2008) An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 36:1198-1201.
147. Remmel RP and Zhou J (2009) UDP-glucuronosyltransferases, in Handbook of Drug Metabolism (Pearson PG and Wienkers LC eds) pp 137-178, Informa Healthcare, New York.
148. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
149. Renwick AB, Ball SE, Tredger JM, Price RJ, Walters DG, Kao J, Scatina JA, and Lake BG (2002) Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 32:849-862.
150. Rettie AE and Jones JP (2005) Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477-494.
151. Rettie AE, Meier GP, and Sadeque AJ (1995) Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase. Chem Biol Interact 96:3-15.
152. Richardson TH, Griffin KJ, Jung F, Raucy JL, and Johnson EF (1997) Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys 338:157-164.
153. Riddle B and Jencks WP (1971) Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate. J Biol Chem 246: 3250-3258.
154. Riley P and Hanzlik RP (1994) Electron transfer in P450 mechanisms. Microsomal metabolism of cyclopropylbenzene and p-cyclopropylanisole. Xenobiotica 24:1-16.
155. Ris MM and von Wartburg JP (1973) Heterogeneity of NADPH-dependent aldehyde reductase from human and rat brain. Eur J Biochem 37:69-77.
156. Robeson M, Zhou H, Moyer C, and Ramanathan S (2013) Pharmacokinetics and safety of idelalisib, a novel PI3Kd inhibitor, in Japanese and Caucasian subjects. Blood 122:5575.
157. Rodriguez RJ and Acosta D, Jr (1997a) Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and flavin-containing monooxygenases. Drug Metab Dispos 25: 772-777.
158. Rodriguez RJ and Acosta D, Jr (1997b) N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 117:123-131.
159. Rodriguez RJ and Buckholz CJ (2003) Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding. Xenobiotica 33:429-441.
160. Roller SG, Dieckhaus CM, Santos WL, Sofia RD, and Macdonald TL (2002) Interaction between human serum albumin and the felbamate metabolites 4-Hydroxy-5-phenyl-[1,3]oxazinan-2-one and 2-phenylpropenal. Chem Res Toxicol 15:815-824.
161. Sane RS, Ramsden D, Sabo JP, Cooper C, Rowland L, Ting N, Whitcher-Johnstone A, and Tweedie DJ (2016) Contribution of major metabolites toward complex drug-drug interactions of deleobuvir: in vitro predictions and in vivo outcomes. Drug Metab Dispos 44:466-475.
162. Satoh T and Hosokawa M (2006) Structure, function and regulation of carboxylesterases. Chem Biol Interact 162:195-211.
163. Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, Sakamoto A, Ishiguro N, Matsumaru T, and Terasaki T, et al. (2012) Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos 40:93-103.
164. Schenkman JB and Jansson I (1999) Interactions between cytochrome P450 and cytochrome b5. Drug Metab Rev 31:351-364.
165. Scott AK (1994) Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet 27:337-344.
166. Shi J, Wang X, Nguyen J, Wu AH, Bleske BE, and Zhu HJ (2016) Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation. Drug Metab Dispos 44:554-559.
167. Shih DM, Wang Z, Lee R, Meng Y, Che N, Charugundla S, Qi H, Wu J, Pan C, and Brown JM, et al. (2015) Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 56:22-37.
168. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
169. Shimizu M, Shiraishi A, Sato A, Nagashima S, and Yamazaki H (2015) Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers. Drug Metab Pharmacokinet 30:70-74.
170. Shin JG, Kane K, and Flockhart DA (2001) Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol 51:45-52.
171. Singh S, Brocker C, Koppaka V, Chen Y, Jackson BC, Matsumoto A, Thompson DC, and Vasiliou V (2013) Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med 56:89-101.
172. Sodhi JK, Wong S, Kirkpatrick DS, Liu L, Khojasteh SC, Hop CE, Barr JT, Jones JP, and Halladay JS (2015) A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos 43:908-915.
173. Song W, Yu L, and Peng Z (2015) Targeted label-free approach for quantification of epoxide hydrolase and glutathione transferases in microsomes. Anal Biochem 478:8-13.
174. Stagos D, Chen Y, Brocker C, Donald E, Jackson BC, Orlicky DJ, Thompson DC, and Vasiliou V (2010) Aldehyde dehydrogenase 1B1: molecular cloning and characterization of a novel mitochondrial acetaldehyde-metabolizing enzyme. Drug Metab Dispos 38:1679-1687.
175. Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47:285-295.
176. Stangier J, Rathgen K, Stähle H, Gansser D, and Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292-303.
177. Strolin Benedetti M (2011) FAD-dependent enzymes involved in the metabolic oxidation of xenobiotics. Ann Pharm Fr 69:45-52.
178. Takai S, Matsuda A, Usami Y, Adachi T, Sugiyama T, Katagiri Y, Tatematsu M, and Hirano K (1997) Hydrolytic profile for ester-or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull 20:869-873.
179. Tamta H, Kalra S, and Mukhopadhyay AK (2006) Biochemical characterization of some pyrazolopyrimidine-based inhibitors of xanthine oxidase. Biochemistry (Mosc) 71 (Suppl 1): S49-S54.
180. Tanaka Y, Nishikawa Y, and Hayashi R (1983) Species differences in metabolism of sodium 2-[4-(2-oxocyclopentylmethyl)-phenyl]propionate dihydrate (loxoprofen sodium), a new antiinflammatory agent. Chem Pharm Bull (Tokyo) 31:3656-3664.
181. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, and Yan B (2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319: 1467-1476.
182. Tang SC, Kort A, Cheung KL, Rosing H, Fukami T, Durmus S, Wagenaar E, Hendrikx JJ, Nakajima M, and van Vlijmen BJ, et al. (2015) P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain disposition and oral availability of the novel taxane cabazitaxel (Jevtana) in mice. Mol Pharm 12:3714-3723.
183. Thomsen R, Rasmussen HB, and Linnet K; INDICES Consortium (2014) In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Drug Metab Dispos 42:126-133.
184. Thorpe LW, Westlund KN, Kochersperger LM, Abell CW, and Denney RM (1987) Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. J Histochem Cytochem 35:23-32.
185. Tohno M, Kimura K, Nagahara M, Sakai Y, Ofuji T, and Nadai T (1979) [Identification of urinary metabolites of befunolol in dog and man principally by mass spectrometry (author's transl)]. Yakugaku Zasshi 99:944-957.
186. Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M, and Backman JT (2014) Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther 96:498-507.
187. Tracy TS, Chaudhry AS, Prasad B, Thummel KE, Schuetz EG, Zhong XB, Tien YC, Jeong H, Pan X, and Shireman LM, et al. (2016) Interindividual variability in cytochrome P450-mediated drug metabolism. Drug Metab Dispos 44:343-351.
188. Trager WF (1989) Stereochemistry of cytochrome P-450 reactions. Drug Metab Rev 20:489-496.
189. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
190. Uehara S, Murayama N, Nakanishi Y, Nakamura C, Hashizume T, Zeldin DC, Yamazaki H, and Uno Y (2015) Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine. Xenobiotica 45:124-130.
191. Umehara KI, Zollinger M, Kigondu E, Witschi M, Juif C, Huth F, Schiller H, Chibale K, and Camenisch G (2016) Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors. Xenobiotica 46:862-867.
192. Václavíková R, Hughes DJ, and Soucek P (2015) Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease. Gene 571:1-8.
193. VandenBrink BM and Isoherranen N (2010) The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Curr Opin Drug Discov Devel 13:66-77.
194. Vannelli TA, Dykman A, and Ortiz de Montellano PR (2002) The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 277:12824-12829.
195. Vermilion JL, Ballou DP, Massey V, and Coon MJ (1981) Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem 256:266-277.
196. Vermilion JL and Coon MJ (1978) Identification of the high and low potential flavins of liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem 253:8812-8819.
197. Virkel G, Lifschitz A, Sallovitz J, Pis A, and Lanusse C (2004) Comparative hepatic and extrahepatic enantioselective sulfoxidation of albendazole and fenbendazole in sheep and cattle. Drug Metab Dispos 32:536-544.
198. Walsh JS, Reese MJ, and Thurmond LM (2002) The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem Biol Interact 142: 135-154.
199. Wang JS, Neuvonen M, Wen X, Backman JT, and Neuvonen PJ (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30: 1352-1356.
200. Weinshilboum RM, Otterness DM, and Szumlanski CL (1999) Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19-52.
201. Wenzl MV, Beretta M, Griesberger M, Russwurm M, Koesling D, Schmidt K, Mayer B, and Gorren AC (2011) Site-directed mutagenesis of aldehyde dehydrogenase-2 suggests three distinct pathways of nitroglycerin biotransformation. Mol Pharmacol 80:258-266.
202. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31: 755-761.
203. Whitehouse LW, Menzies A, Dawson B, Zamecnik J, and Sy WW (1990) Deacetylated ketoconazole: a major ketoconazole metabolite isolated from mouse liver. J Pharm Biomed Anal 8:603-606.
204. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
205. Williams RT (1969) The fate of foreign compounds in man and animals. Pure Appl Chem 18: 129-141.
206. Wirth H and Wermuth B (1992) Immunohistochemical localization of carbonyl reductase in human tissues. J Histochem Cytochem 40:1857-1863.
207. Xu G, Zhang W, Ma MK, and McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8: 2605-2611.
208. Xu M, Ju W, Hao H, Wang G, and Li P (2013) Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance. Drug Metab Rev 45:311-352.
209. Yang Z, Chen M, and Nadler JL (2005) Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol 69:1-5.
210. Yeung CK, Fujioka Y, Hachad H, Levy RH, and Isoherranen N (2011) Are circulating metabolites important in drug-drug interactions?: quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105-113.
211. Youdim MBH, Edmondson D, and Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309.
212. Yu H and Tweedie D (2013) A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency. Drug Metab Dispos 41:536-540.
213. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, and Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585.
214. Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138: 103-141.
215. Zhang X, Liu HH, Weller P, Zheng M, Tao W, Wang J, Liao G, Monshouwer M, and Peltz G (2011) In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 11:15-24.
216. Zhu X, Yun W, Sun X, Qiu F, Zhao L, and Guo Y (2014) Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics 15:1867-1879.
217. Ziegler DM (1990) Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity. Trends Pharmacol Sci 11:321-324.
218. Zientek M, Jiang Y, Youdim K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322-1327.